The once lucrative heart-drug market is now poised to make a comeback, but at the cost of heavy investments in research and deal making.
After watching lower-priced generics seize sales of once-highflying blood-pressure, cholesterol and other heart drugs, companies struggled to discover replacements and then win reimbursement for five-figure prices. Drugmakers are now rolling out new medicines, though their commercial prospects are uncertain.
Resumimos esta notícia para que você possa lê-la rapidamente. Se você se interessou pela notícia, pode ler o texto completo aqui. Consulte Mais informação: